These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 3955625)

  • 1. Mathematical model for human myeloma relating growth kinetics and drug resistance.
    Hokanson JA; Brown BW; Thompson JR; Jansson B; Drewinko B
    Cell Tissue Kinet; 1986 Jan; 19(1):1-10. PubMed ID: 3955625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prognostic factors in multiple myeloma].
    Boccadoro M; Bianchi A; Dianzani U; Frieri R; Gallone G; Massaia M; Omede P; Palumbo A; Pileri A
    Haematologica; 1989 Oct; 74(5 Suppl):347-57. PubMed ID: 2512219
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical staging and new therapeutic approaches in multiple myeloma.
    Salmon SE; Durie BG
    Recent Results Cancer Res; 1978; 65():12-20. PubMed ID: 370937
    [No Abstract]   [Full Text] [Related]  

  • 4. The use of cell kinetics in the development of drug combinations.
    Valeriote FA
    Pharmacol Ther; 1979; 4(1):1-33. PubMed ID: 461499
    [No Abstract]   [Full Text] [Related]  

  • 5. Tumor growth patterns in multiple myeloma.
    Hokanson JA; Brown BW; Thompson JR; Drewinko B; Alexanian R
    Cancer; 1977 Mar; 39(3):1077-84. PubMed ID: 912647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal control applications in the chemotherapy of multiple myeloma.
    Swan GW
    IMA J Math Appl Med Biol; 1985; 2(3):139-60. PubMed ID: 3870983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of intra-clonal heterogeneity on the treatment of multiple myeloma.
    Brioli A; Melchor L; Cavo M; Morgan GJ
    Br J Haematol; 2014 May; 165(4):441-54. PubMed ID: 24580032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New aspects in the clinical course determination and therapy in multiple myeloma].
    Ludwig H; Pietschmann H
    Acta Med Austriaca; 1979; 6(5):255-60. PubMed ID: 555224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
    Park J; Park E; Jung CK; Kang SW; Kim BG; Jung Y; Kim TH; Lim JY; Lee SE; Min CK; Won KA
    BMC Cancer; 2016 Mar; 16():247. PubMed ID: 27012957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug resistance in multiple myeloma: novel therapeutic targets within the malignant clone.
    Pilarski LM; Mant MJ; Belch AR
    Leuk Lymphoma; 1999 Jan; 32(3-4):199-210. PubMed ID: 10037018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth kinetics of plasma cell myeloma.
    Drewinko B; Alexanian R
    J Natl Cancer Inst; 1977 May; 58(5):1247-53. PubMed ID: 857025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A mathematical model of the development of drug resistance to cancer chemotherapy.
    Birkhead BG; Rankin EM; Gallivan S; Dones L; Rubens RD
    Eur J Cancer Clin Oncol; 1987 Sep; 23(9):1421-7. PubMed ID: 3678329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The multiple myeloma--current view and perspectives].
    Knop S
    Med Monatsschr Pharm; 2014 Mar; 37(3):84-92; quiz 93-4. PubMed ID: 24741848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumour-associated macrophage-mediated survival of myeloma cells through STAT3 activation.
    De Beule N; De Veirman K; Maes K; De Bruyne E; Menu E; Breckpot K; De Raeve H; Van Rampelbergh R; Van Ginderachter JA; Schots R; Van Valckenborgh E; Vanderkerken K
    J Pathol; 2017 Mar; 241(4):534-546. PubMed ID: 27976373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting bone in myeloma.
    Morgan GJ; Wu P
    Recent Results Cancer Res; 2012; 192():127-43. PubMed ID: 22307373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?
    Franqui-Machin R; Wendlandt EB; Janz S; Zhan F; Tricot G
    Oncotarget; 2015 Dec; 6(38):40496-506. PubMed ID: 26415231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetics of tumor growth and regression in IgG multiple myeloma.
    Sullivan PW; Salmon SE
    J Clin Invest; 1972 Jul; 51(7):1697-708. PubMed ID: 5040867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Intracellular Signaling Pathways in the Pathogenesis of Multiple Myeloma and Novel Therapeutic Approaches.
    Kizaki M; Tabayashi T
    J Clin Exp Hematop; 2016; 56(1):20-7. PubMed ID: 27334854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomib.
    Malek E; Driscoll JJ
    Oncotarget; 2016 Jun; 7(25):38523-38538. PubMed ID: 27229530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Mechanisms of drug resistance and sensitivity concerning novel agents for multiple myeloma].
    Tokuhira M
    Rinsho Ketsueki; 2016 May; 57(5):563-74. PubMed ID: 27263780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.